P-127: Efficacy of olmesartan medoxomil (OLM), losartan potassium (LOS) and valsartan (VAL) in a non-black patient (PT) cohort

This 12-wk, randomized, double-blind, forced-titration study compared the antihypertensive efficacy of the angiotensin II receptor blocker (ARB) OLM with VAL and LOS across all recommended doses and dosing regimens. Pts with stage 2 hypertension (N=723; 79% non-black, 21% black) were randomized to OLM 20mg (n=207), VAL 80mg (n=203), LOS 50mg (n=207) or placebo (PLA; n=106), once daily. At wk 4, doses were titrated to: OLM 40mg, VAL 160mg and LOS 100mg, once daily for 4 wks. At wk 8, pts taking OLM remained at 40mg once daily (maximum recommended dose) for an additional 4 wks, pts taking VAL were titrated to 320mg daily, and pts taking LOS were titrated to 50mg twice daily. The primary endpoint was the mean change in cuff seated diastolic blood pressure (SeDBP) from baseline to wk 8. Secondary efficacy variables included the mean change in cuff seated systolic BP (SeSBP). Wk 12 analysis was designed to show equivalence of the treatments. A secondary analysis was performed to determine BP goal rates (